FRLN - Freeline Therapeutics Holdings plc: The Losing Streak Continues (FRLN)
Shares of Freeline Therapeutics Holdings plc (NASDAQ:FRLN) traded at a new 52-week low today of $5.38. So far today approximately 478,000 shares have been exchanged, as compared to an average 30-day volume of 214,000 shares.
Over the past year, Freeline Therapeutics Holdings plc has traded in a range of $5.38 to $21.69 and is now at $5.50.
There is potential upside of 11.4% for shares of Freeline Therapeutics Holdings plc based on a current price of $5.50 and an average consensus analyst price target of $6.13.
Freeline Therapeutics Holdings PLC is a clinical-stage biotechnology company developing transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its lead product candidates are FLT180a for the treatment of hemophilia B, and FLT190 for the treatment of Fabry disease.
Receive IBN Spotlights - "Bite Size" Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer